Biohaven Ltd. - BHVN STOCK NEWS

Biohaven Pharmaceutical holds announced preliminary net product revenue of $35 million for NURTEC ODT in Q4 2020, a staggering 98% increase compared to Q3. Total prescriptions for 2020 exceeded 337,000 with over 24,000 unique prescribers. The revenue projection is preliminary and based on unaudited data. CEO Vlad Coric highlighted strong market momentum despite pandemic challenges, noting positive feedback from patients and physicians. NURTEC ODT, a CGRP receptor antagonist, was FDA-approved for migraine treatment in February 2020 and launched in March.

Biohaven Pharmaceuticals (NYSE:BHVN) has signed Cody Ware to pilot the Nurtec® ODT #51 Chevrolet Camaro for the 2021 NASCAR Cup Series season. The partnership kicks off at the DAYTONA 500 on February 14. Ware, who has personal experience with migraines, aims to raise awareness about the condition and Nurtec ODT, the first and only FDA-approved CGRP receptor antagonist in an orally disintegrating tablet form for acute migraine treatment. Biohaven's CEO expressed excitement about this collaboration, highlighting the importance of effective migraine treatments.

Biohaven Pharmaceutical (BHVN) announced the results of its Phase 2/3 trial of troriluzole for treating mild-to-moderate Alzheimer's disease. The drug did not show a statistically significant difference from placebo on co-primary endpoints at 48 weeks. However, a subgroup analysis indicated a non-significant numerical benefit in mild AD patients. Full results, including additional biomarker analyses, will be available soon. The treatment was well-tolerated, prompting plans for an amendment to the ongoing long-term study to gather more data.

Biohaven Pharmaceutical (NYSE: BHVN) announced its acquisition of the remaining 58% stake in Kleo Pharmaceuticals, enhancing its portfolio with innovative bispecific compounds for immunotherapy. The acquisition, valued at approximately $20 million, allows Biohaven to integrate Kleo's chemistry capabilities at the newly established Biohaven Labs in New Haven, Connecticut. Additionally, Biohaven secured an exclusive license from Yale University for a novel extracellular degrader technology. This strategic move positions Biohaven to expand its product development in oncology and autoimmune disorders.

Biohaven Pharmaceuticals (NYSE:BHVN) announced that its migraine treatment, Nurtec ODT, will sponsor the #51 Ligier JS P217 at the 2021 24 Hours of Daytona race. This event, taking place at Daytona International Speedway on January 30-31, marks a significant partnership with Eurasia Motorsports and BAM Motorsports Management. Drivers Austin Dillon and Cody Ware will pilot the car. CEO Vlad Coric emphasized the importance of raising awareness for migraine disease through this initiative. Nurtec ODT, the first orally disintegrating tablet for migraine relief, received FDA approval in February 2020.

Biohaven Pharmaceutical Holding Company (BHVN) has begun enrollment for a Phase 3 clinical trial to examine the safety and efficacy of troriluzole in patients with obsessive-compulsive disorder (OCD). The trial involves a 280 mg once-daily dose and aims to enroll approximately 600 patients across both the U.S. and Europe. Previous Phase 2 studies indicated a clinically meaningful effect, despite lacking statistical significance. This trial is crucial as no new OCD treatments have been approved in over two decades, and approximately one-third of OCD patients do not respond to current therapies.

Biohaven Pharmaceutical (NYSE: BHVN) announced positive results from a Phase 3 clinical trial of rimegepant for migraine prevention, published in The Lancet. Rimegepant significantly reduced monthly migraine days compared to placebo, with a noted reduction of −4.3 days over the treatment period. The FDA previously approved rimegepant for acute migraine treatment in February 2020. This represents a breakthrough as it demonstrates the efficacy of rimegepant for both acute and preventive migraine therapy. A supplemental New Drug Application for preventive use is under review with a PDUFA goal date in 2Q2021.

Biohaven Pharmaceuticals (NYSE:BHVN) has partnered with Rick Ware Racing for the 2021 NASCAR Cup Series, featuring Nurtec™ ODT as the primary sponsor for the No. 51 car. Approved by the FDA in February 2020 for acute migraine treatment, Nurtec ODT is the first orally disintegrating tablet in its category. This partnership aims to raise awareness about migraine relief among the nearly 40 million individuals affected in the U.S. The team will also participate in the Military Salutes Program, visiting 50 military bases to support troops who may suffer from migraines.

Biohaven Pharmaceutical (NYSE: BHVN) recently announced a value-based contract with Prime Therapeutics for its migraine treatment, NURTEC ODT (rimegepant), addressing the needs of the 55% of migraine patients who find current treatments inadequate. The contract aims to protect health plans financially from high usage while ensuring that the medication's price aligns with its value. NURTEC ODT, FDA-approved in February 2020, offers quick relief, with effects felt within an hour, catering to a significant unmet need among nearly 40 million U.S. migraine sufferers.